The generalized myasthenia gravis (gMG) market is experiencing significant growth with 8 promising late-stage drug candidates in development. The gMG market across 7 major markets was valued at USD 5.9 billion in 2025 and is projected to grow at 9.1% CAGR through 2036. Key therapies in development include FcRn inhibitors, complement inhibitors, BTK inhibitors, and innovative CAR-T cell therapies from major pharmaceutical companies.

Immunovant reported that its two Phase 3 clinical studies of batoclimab for thyroid eye disease (TED) failed to meet their primary endpoint of ≥2mm proptosis responder rate at Week 24. However, safety results were consistent with previous findings with no new safety signals. The company remains focused on advancing IMVT-1402 in multiple autoimmune indications, with Graves' disease as a key priority and registrational study data expected in 2027.

Immunovant reported Q3 2025 financial results with a net loss of $110.6 million. The company's IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis is fully enrolled with topline data expected in H2 2026. A $550 million financing was completed in December 2025, extending cash runway through potential Graves' disease launch. Development remains on track across multiple indications including GD, MG, CIDP, and SjD.

Roivant Sciences purchased 16.7 million shares of Immunovant for $350 million, increasing its ownership to 64.65% of outstanding shares. The biotech company focuses on monoclonal antibody therapies for autoimmune diseases and is currently in clinical trials for its lead drug candidate.

Law firm Kahn Swick & Foti, LLC has initiated an investigation into Century Aluminum Company, examining potential breaches of fiduciary duties or violations of state/federal laws by its officers and directors.

Immunovant's stock gained 11% after reporting positive results from a proof-of-concept study for batoclimab, an investigational drug targeting Grave's disease. The study showed 17 out of 21 patients maintained normal thyroid function six months after treatment.

Immunovant presented promising six-month off-treatment data for batoclimab in Graves' disease, showing ~80% of patients maintained normal thyroid function and ~50% achieved anti-thyroid drug-free remission.

Immunovant reported a widened net loss of $0.71 per share in Q1 FY2026, with increased research and development expenses of $101.2 million as the company advanced clinical trials for its lead anti-neonatal Fc receptor antibody IMVT-1402 across six different studies.

Immunovant's (IMVT) investigational candidate, batoclimab, showed positive data in a mid-stage study for Graves' Disease, leading to a rise in the company's stock. The data demonstrated significant reductions in Immunoglobin G levels and high response rates in the patient population.

Immunovant's batoclimab achieved a 76% response rate in Graves' Disease patients uncontrolled on antithyroid drugs (ATDs) at week 12. The company also reported a strong correlation between IgG lowering and clinical outcomes, indicating a potential best-in-class and first-in-class opportunity for IMVT-1402 in Graves' Disease.

The thyroid eye disease market is expected to show good positive growth by 2034, driven by new product launches, a robust pipeline of emerging therapies, and an increase in the geriatric population.

Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.